Because PPARγ was described to be the key functional receptor transducing the effects of commonly prescribed anti-inflammatory amino salicylates in inflammatory bowel disease (IBD) patients [65], augmenting PPARγ expression represents a promising approach for the clinical management of gluten induced intestinal inflammation [66]. This evidence concerns the gene PPARG and irritable bowel syndrome.